Gunnar H. Gislason

Current employment

From January 2010: Senior Consultant Cardiologist (overlæge) Cardiac Imaging and Senior Research Scientist, Department of Cardiology, Gentofte University Hospital

From August 2008: Associate Professor, Faculty of Health Sciences, University of Copenhagen

Education and Degrees

1992 MD University of Iceland                                       2003 Specialist in Internal Medicine

2008 Ph.D. University of Copenhagen                          2009 Specialist in Cardiovascular Diseases

Research and Scientific Activity

My main fields of research are large-scale register based studies within cardiovascular epidemiology and pharmacoepidemiology. I have defended a PhD thesis within this field. I have extensive experience working with the Danish national registries and I have developed methods to manage and analyse data. Advanced programming in SAS and Stata statistical systems.

Author/co-author of 106 articles published in peer-reviewed journals and more than 150 abstracts presented at international congresses. I hold key publications in the Lancet, Circulation (7), JACC (3), Annals of Internal Medicine, BMJ (4), Archives of Internal Medicine (2) and European Heart Journal (5). My h-index is 19; the number of publications in 2010 was 25 and there were 28 publications in 2011.

I am advisor on 9 completed and 10 on-going PhD projects.

Other Experience and Professional Memberships

Chairman of the Danish Society of Pharmacoepidemiology (since 2009) and member of the board of Danish Society of Pharmacology.

Fellow of the European Society of Cardiology  (FESC) and member of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy

Fellow of the American College of Cardiology (FACC)

Chairman of the NSAID working group for the Danish Cardiac Society

Reviewer on several international journals including: JAMA, BMJ, European Heart Journal, American Journal of Cardiology, Canadian Medical Association Journal, Pharmacoepidemiology and Drug Safety, Journal of Hypertension, QJM, Cardiology, European Journal of Heart Failure. Sentinel reader for the McMaster Online Rating of Evidence and the American College of Physicians. Reviewer of grant applications for the Health and Health Services Research Fund of Hong Kong SAR government.

Research leadership and Administrative Experience

Leading role in several research projects and co-leader of a research group of 30 persons.

Chief physician in charge of the anticoagulation clinic at Gentofte Hospital.

Completed Gentofte Hospital leadership programme for consultants and an internal leader course.

Board member of the cardiovascular research programme steering committee, Faculty of Health Sciences, University of Copenhagen


Awarded the Novo Nordisk Foundation 5 year Research Scholarship in 2012

My presentation at the 2005 American Heart Association Scientific Sessions on risk of death associated with the use NSAIDs after MI was selected as one of the highlights of the congress.

My article on Cardiovascular risk of NSAIDs (Circulatio 2006;113:2906-13) was selected as the second most important cardiovascular research advances in 2006 by the American Hearth Association.

Selected 10 Publications (total number 106)

  1. Gislason GH, Rasmussen JN, Abildstrom SZ, Rasmussen S, Buch P,      Friberg J, Gadsbøll N, Køber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting      enzyme inhibitors and statins after acute myocardial infarction. European Heart Journal 2006;27:1153-8
  2. Gislason GH, Jacobsen S, Rasmussen JN,      Abildstrom SZ, Buch P, Friberg J, Schramm TK, Rasmussen S, Køber L, Madsen      M, Torp-Pedersen C. Risk of death      or reinfarction associated with treatment with selective      cyoclo-oxygenase-2 inhibitors and non-selective non-steroidal      anti-inflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13
  3. Gislason GH,      Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sørensen R, Gadsbøll      N, Rasmussen S, Køber L, Madsen M, Torp-Pedersen C. Persistent use of      evidence-based pharmacotherapy in heart failure is associated with      improved outcomes. Circulation      2007;116:737-44
  4. Gislason GH, Rasmussen      JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F,      Buch P, Gadsbøll N, Rasmussen S, Poulsen HE, Køber L, Madsen M,      Torp-Pedersen C. Increased mortality and cardiovascular morbidity      associated with use of non-steroidal anti-inflammatatory drugs in chronic      heart failure. Arch of Int Med 2009;169(2):141-9
  5. Sørensen R, Hansen ML, Abildstrøm SZ, Hvelplund      A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen      C, Gislason GH. Bleeding risk in patients with acute myocardial      infarction treated with different combinations of aspirin, clopidogrel and      vitamin K antagonists: a nationwide study of 40 812 patients. The Lancet 2009;374:1967-74.
  6. Folke F, Gislason GH,      Lippert FK, Nielsen SL, Weeke P, Hansen ML, Fosbøl EL, Andersen SS,      Rasmussen S, Schramm TK, Køber L, Torp-Pedersen C. Differences between      out-of-hospital cardiac arrest in residential and public locations and      implications for public access defibrillation. Circulation 2010;122:623-30
  7. Charlot M, Ahlehof O, Jørgensen CH, Hansen PR, Madsen JK, Køber L,      Torp-Pedersen C, Gislason GH. Proton Pump Inhibitors are associated with      Increased Cardiovascular Risk Independent of Clopidogrel Use: A Nationwide      Study. Annals of Internal Medicine      2010; 153:378-86
  8. Olsen AMS, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Olesen JB, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH.  Duration of Treatment with Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients with Prior Myocardial Infarction – A Nationwide Cohort Study. Circulation 2011; 123:2226-2235
  9. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, Lindhardsen J, Madsen JK, Køber L, Torp-Pedersen C, Gislason GH. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. British Medical Journal 2011;342:d2690.
  10. Bretler DM, Hansen PR, Sørensen R, Lindhardsen J, Ahlehoff O,      Andersson C, Abildstrøm SZ, Torp-Pedersen C, Gislason GH. Discontinuation      of hormone replacement therapy after myocardial infarction and short-term      risk of adverse cardiovascular events: a nationwide cohort study. BMJ 2012 ;344:e1802